KR20180034021A - Animal model for lipodystrophy, preparation method thereof, and screening method for lipodystrophy therapeutic agent using the same - Google Patents

Abstract

Provided are an animal model useful for studying progression and pathological mechanisms of lipodystrophy, a method for producing the animal model, and a method for screening a treatment and preventive agent for lipodystrophy using the animal model. By selecting a regulatory substance for lipodystrophy by using the animal model of the present invention, the animal model can be useful in screening to verify therapeutic effects.

Description

TECHNICAL FIELD The present invention relates to an animal model for lipodystrophy, a method for producing the lipodystrophy animal model, and a screening method for treating a lipodystrophy therapeutic agent using the same.

The present invention relates to an animal model of lipodystrophy and a method for producing the same, and further, to a method for screening a therapeutic agent for lipodystrophy using the animal model.

Unlike other lipid metabolites, sphingolipids are controlled by biosynthesis by inflammation and various cytokines and have been reported to be increased in various tissues of obese and diabetic animal models (Non-Patent Document 1). In addition, since intracellular concentration is regulated by the concentration of fatty acid which is a biosynthetic substrate of sphingolipids, it is sensitively controlled to the concentration of fatty acids in blood increased by obesity (Non-Patent Document 2). In particular, the role of sphingolipid has been elucidated in studies on obesity-induced metabolic pathology and is known to be involved in arteriosclerosis, diabetes, and cardiomyopathy. Pharmacological studies using genetic mutant animal models and sphingos biosynthesis inhibitors have identified their therapeutic efficacy and its mechanism.

The biosynthesis of sphingolipids is accomplished by the condensation process of serine with palmitoyl CoA (palmitoyl CoA, C16: 0) which is one of fatty acid CoA which is a precursor, by serine palmitoyltransferase (SPT) We start with the production of 3-ketosphinganine. SPT consists of SPTLC1 and SPTLC2 subunits and is known to be a key step enzyme for controlling sphingolipid biosynthesis (Non-Patent Document 3).

In order to inhibit ceramide biosynthesis, pharmacological studies on ceramide biosynthesis, sphingomyelinase, serine palmitoyltransferase, 3-ketosphinganine reductase, Studies have been made on compounds that inhibit at least one enzyme among enzymes (ceramide synthase) and dihydroceramide desaturase (Patent Document 1-2).

U.S. Patent Publication No. 2005-0182020 (Aug. 18, 2005) U.S. Patent Publication No. 2010-0086543 (Apr. 4, 2010)

Merrill, A. H., Jr. (2002) De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Bio Chem. 277, 25843-25846 Kuller, L.H. (2006) Nutrition, lipids, and cardiovascular disease, Nutr Rev. 64, S15-26 Hanada, K. (2003) serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochem Biophys Acta. 1632, 16-30. The Journal of Biological Chemistry, 280, 10284-10289. March 18, 2005. Xian-Cheng Jiang

It is an object of the present invention to provide an animal model that is useful for the study of progression and pathological mechanism of lipodystrophy.

Another object of the present invention is to provide a method for producing the animal model.

It is still another object of the present invention to provide a method for screening a therapeutic and / or therapeutic agent for lipodystrophy using the animal model.

According to one aspect of the present invention, there is provided an animal model of lipodystrophy characterized in that the adipocyte-specific SPTLC2 gene is a knock-out mouse.

In one embodiment, the mouse may be an animal model of lipodystrophy characterized by a homozygote.

In one embodiment, the lipid disorder is any one selected from the group consisting of fatty liver, systemic insulin resistance, and hypertonicity.

According to one aspect of the present invention, there is provided a method of preparing a mouse, comprising: (a) preparing a mouse having a floxed SPTLC2 mouse and an adiponectin-Cre transplant gene; (b) obtaining a second generation mouse by crossing a mouse with a plastose SPTLC2 mouse and an adiponectin-Cre transplantation gene; And (c) selecting an adipocyte-specific SPTLC2 gene-deficient mouse from the second-generation mouse obtained in step (b).

According to one aspect of the present invention, there is provided a method of treating an animal model comprising: (i) administering a sample to an animal model of lipid disorder; (ii) measuring the symptoms of lipodystrophy of the animal model after administration of the sample; And (iii) selecting a sample that alleviates the symptoms of lipodystrophy in comparison with a control group to which the sample is not administered.

In one embodiment, the symptom of lipodystrophy of step (ii) is the content of ceramide, sphingomyelin, sphingoid base and diacylglycerol of epididymal WAT; Plasma ceramide, dihydroceramide, sphingomyelin and sphingoid base content; Expression of hepatic cholesterol or liver triglyceride (TG) content, TG biosynthesis gene or fatty acid oxidase gene; The content of ceramide, sphingomyelin, sphingoid base and diacylglyceride; And expression of a lipogenic gene of a skeletal muscle. The screening method may further comprise:

The animal model according to the present invention is characterized in that it is a homozygote due to fat cell specific SPTLC2 gene deletion and is any one selected from the group consisting of fatty liver, systemic insulin resistance and hypertonic papilloma. It is a model. The animal model of the present invention is an animal model for the downregulation of adipocytic genes in epididymal WAT, a decrease in C18: 1 sphingomyelin, a rise in C16: 0 and C24: 1 ceramides, a rise in sphinganine, a rise in sphingosine, a decrease in S1P; Upregulation of lipogenic genes in liver, reduction of C24: 0 and C24: 1 ceramides, elevation of DAG levels; It has been confirmed that symptoms of lipodystrophy such as elevation of plasma glucose level, increase of cholesterol level, upregulation of HMG CoR, decrease of unesterified FA level and increase of ketone body represented by beta-hydroxybutyrate are shown. Therefore, the animal model according to the present invention can be usefully used as an animal model of progression of lipodystrophy and pathological mechanism studies.

In addition, by using an animal model of lipodystrophy according to the present invention, a lipodystrophy regulating substance can be selected and used for screening to verify its therapeutic effect.

FIG. 1 shows that the 'hyperlipidemia state' according to the day of differentiation is caused by the sphingolipid neogenesis in adipose tissue and differentiated 3T3-L1 adipocytes fed high-fat diet (HFD) Activated '. Wild type (WT) C57BL / 6 mice were fed high fat diet (HFD) (60 kcal% fat) for 8 weeks, and white adipose tissue (WAT) of the epididymis was isolated. mRNA was extracted for qRT-PCR analysis (A), and tissue lysates were analyzed by immunoblotting for SPTLC1, SPTLC2 and SPHK1 (B). Data were expressed as mean ± SEM (* p <0.05, n = 6). 3T3-L1 cells were differentiated for 7 days and harvested at designated days (D0, D2, D4, D5 and D7). QRT-PCR was performed to measure the expression of the sphingolipid biosynthetic gene (C, E). Cell lysates were analyzed by immunoblotting for SPTLC1, SPTLC2, and SPHK1 (E) (mean ± SEM, * p <0.05 [3T3-L1 control compared to D0], n = 3).
Figure 2 shows the expression of aCer1 / 2/3 (AC ceramidase 1/2/3) (AC), AcCer (acid ceramidase) (D) and nCer (neutral ceramidase) (E) according to the day of differentiation . 3T3-L1 cells were differentiated for 7 days and harvested on designated days (D0, D2, D4, D5 and D7). To measure mRNA expression, qRT-PCR was performed (mean ± SEM, * p <0.05 [3T3-L1 compared to D0 in the control group], n = 3).
Figure 3 shows that inhibition of SPTLC2 reduces fat accumulation and downregulates obesity genes. A stable 3T3-L1 strain (shRNA-SPTLC2) in which SPTLC2 was specifically removed was prepared using lentivirus. shRNA-SPTLC2 cells reduced SPTLC2 protein and mRNA (A). During the differentiation of 3T3-L1 cells, the expression of SPTLC2 was reduced in control and SPTLC2-inhibited cells (B). Fat accumulation was measured using the AdipoRed Assay as described in the Examples (C). To determine the expression of SPHK1 / 2, aP2, C / EBPalpha, PPARy, PEPCK, SREBP-1c and GLUT4 according to the day of differentiation by differentiating 3T3-L1 control cells and SPTLC2- pR &lt; 0.05 [shRNA-SPTLC2 < / RTI &gt; cells (compared to the control of each day), p < 0.05 D0 contrast], n = 3).
FIG. 4 shows that lipodystrophy occurred in 'a SPTLC2 KO mice with SPTLC2-specific adipocytes removed'. Multiple tissues were isolated from aSPTLC2 KO mice and the expression of SPTLC2 was examined by immunoblotting (A). Mice were fed high fat diet (45 kcal% fat, for 8 weeks) and fat tissue size was measured (B). The reference indicates 1 cm. The white adipose tissue section of the epididymis was stained with hematoxylin and eosin (H & E) or F4 / 80 antibodies (C). (D) (mean ± SEM, * p <0.05 [compared with plucked mouse], n = 5). The expression of adipogenic gene was measured by isolating the adipose tissue white adipose tissue (WAT). Analysis on ceramide, sphingomyelin (SM) (E), sphingoid base and diacylglycerol (DAG) (F) was performed with LC-MS / MS (mean ± SEM, * p <0.05 [Compared to flocked mouse], n = 5-6).
Figure 5 shows the 'plasma sphering loop feed profile'. Mice were fed a normal food diet (NCD) or a high fat diet (HFD, 45 kcal% fat) for 8 weeks and plasma samples were collected. The analysis of ceramide (A), dihydroceramide (B), sphingomyelin (C) and sphingoid bases (D) was performed using LC / MS / MS SEM. * P <0.05 [compared to flocked mice fed a normal diet], #p <0.05 [compared to flocked mice fed high-fat diet], n = 5-6).
Figure 6 shows that 'aSPTLC2 KO mice developed fatty liver.' Flocked mice and aSPTLC2 KO mice were fed a normal diet (NCD) or high fat diet (HFD) (45 kcal% fat) for 8 weeks. The mouse liver was separated and the frozen section was stained with Oil Red O (ORO) (A) in order to check the liver in the liver. The standard indicates 100 μm. Liver cholesterol and triglyceride (TG) (B) were measured. Expression of TG (triglyceride) biosynthetic gene (C) and fatty acid (FA) oxidized gene (D) was measured by qRT-PCR. Analysis of ceramide, SM (E), sphingoid base and diacylglycerol (DAG) (F) was performed by LC-MS / MS (mean ± SEM, * p <0.05 [ (Compared to flocked mice fed high-density lipoprotein (HFD)), n = 5-6).
Figure 7 shows the expression of genes that synthesize fats in rat skeletal muscle after ingestion of normal food diet (NCD) or high fat diet (HFD). Plastost and aSPTLC2 KO mice were sacrificed after 8 weeks of high fat diet (45 kcal% fat). Quantitative RT-PCR analysis was performed to determine the expression of fat biosynthesis genes (mean ± SEM, * p <0.05 [compared to flocked mice fed a normal diet], n = 5-6).
Figure 8 shows that aSPTLC2 KO mice are resistant to obesity induced by high fat diet (HFD), but produce insulin resistance. Plastost and aSPTLC2 KO mice were fed a normal diet (NCD) and high fat diet (HFD) (60 kcal% fat) for 6 weeks. Body weights (A) and body fat composition (B) of the plastost and aSPTLC2 KO mice were analyzed weekly by ¹ H NMR (mean ± SEM, * p <0.05 [ (Compared with aSPTLC2 KO mice fed a normal food diet (NCD), n = 10-14). To determine glucose uptake rate (GIR), hepatic glucose production (HGP) inhibition (C), basal hepatic glucose production (BHGP), and hepatic glucose production during clamping (CHGP) (D), hyperinsulinemic normoglycan clamp Respectively. Independently, plastost and aSPTLC2 KO mice were administered intraperitoneally with insulin (0.5 unit / kg body weight). Liver (E) and subcutaneous adipose tissue (F) were isolated after 10 minutes of insulin injection and immunoblot analysis was performed to determine pAKT levels (mean ± SEM, * p <0.05 [ N = 10-14, body weight, fat mass, and lean body mass).
Figure 9 shows the food intake of plastost and aSPTLC2 KO mice. Food intake was measured weekly for 4 weeks (mean ± SEM, n = 10-14, food intake) during normal diet (NCD) or high fat diet (HFD, 60 kcal% fat) .
Figure 10 shows metabolic changes in plastost and aSPTLC2 KO mice. Four weeks after the normal diet (NCD) and high fat diet (HFD, 60 kcal% fat), oxygen consumption (VO2) (A), carbon dioxide Basic energy balance including velocity (VCO2) (B), respiratory rate (C), energy consumption (D), food intake (E) and activity (F) N = 10) compared to those with a food diet.
Figure 11 shows the results for additional hyperinsulinemic normal blood glucose clamps and glucose flux. Fasting glucose was measured for fasting glucose (B), sugar solution (C) and glycogen synthesis rate (D) in the whole body after 6 weeks of high fat diet and fasting overnight. Fasting glucose, Glucose uptake, Glycolysis, Glucose uptake (mean ± SEM, * p <0.05 [compared to flocked mice fed high-fat diet], n = Glycogen synthesis rate).
Figure 12 shows that elevation of sphingosine-1-phosphate (S1P) during blood circulation caused adipocyte hypertrophy. 8-week-old plastost and aSPTLC2 KO mice were fed high fat diet (HFD) (60 kcal% fat) for 2 weeks and adenovirus containing GFP or SPHK2 (1 × 10 ⁹ PFU) was injected into the tail vein. Two weeks after injection, the body fat composition was measured by ¹ H NMR (A) and the adipose tissue was stained with hematoxylin and eosin (B) (mean ± SEM, * p <0.05 [ 0 week) contrast], n = 5). S1P receptor expression was measured (C) (mean ± SEM, * p <0.05 [compared to flocked mice fed high-fat diet (HFD)], n = 5-6). QRT-PCR analysis was performed to determine the expression of S1P receptor (DF) (mean ± SEM, * p <0.05 [control D0 contrast], #p <0.05 [control for each date], n = 3, day of differentiation).
FIG. 13 shows that 'sphingosine-1-phosphate (S1P) activates the proliferation of PPARγ and 3T3-L1 pre-adipocytes'. 3T3-L1 pre-adipocytes were treated for 24 hours with S1P or without S1P, and the migration pattern to the scratched area was observed under various S1P conditions (A). Cell migration was measured by a wound-healing assay and quantified by the ratio of gap distances at 0 h and at 24 h (B). The gap standardized the values after capturing three random points. 3T3-L1 cell viability was evaluated by XTT assay after treatment with increasing S1P concentration for 24 hours (C). AML-12 cells were transiently transfected with a vector containing the PPRE-x3-TK-luc construct and the cells were treated with 5 [mu] M S1P or 10 [mu] M rosiglitazone for 6 hours. Thereafter, the luciferase activity was measured using a luminometer (D) (mean ± SEM, * p <0.05 [control group], n = 5-6).
14 shows comparative data distinguishing between homozygous mice and heterozygous mice. In order to confirm LoxP insertion, the mouse tail was cut about 0.5 cm, the tissue was digested with proteinase K, PCR was performed to detect products at 366 bp when LoxP was inserted and products at 205 bp for wild type, and homozygous mouse and heterozygous mouse were distinguished from each other. The presence of adiponectin-Cre Were also identified by polymerase chain reaction to distinguish between adipose tissue specific SPTLC2 mice and flocked mice.

In the present specification, 'SPTLC2' means one of subunits constituting serine palmitoyltransferase (SPT), which is known as a main step enzyme for controlling sphingolipid biosynthesis. SPT is composed of SPTLC1 and SPTLC2 (Tae Sik Park, Sphingolipids and Metabolic Diseases, Biochemical Molecular Biology Society, December 2010).

In the present specification, 'prokst mouse' is a mouse in which exon1 of the SPTLC2 gene is sandwiched between two recombinant enzyme-binding base sequences loxP sites.

The present invention provides an animal model of lipodystrophy characterized by that the adipocyte-specific SPTLC2 gene is a knock-out mouse. The present invention is an animal model of lipodystrophy characterized by being homozygote, wherein the lipodystrophy is any one selected from the group consisting of fatty liver, systemic insulin resistance and hypertonic papilloma But is not limited thereto.

On the other hand, prior art US 2008-0249174 A1 (JIANG, Xian-cheng) discloses SPTLC1 and SPTLC2 whole-body heterozygous SPTLC2 knock-out mice (- / +), Although no abnormalities have been studied, the present invention is differentiated in that adipocyte-specific SPTLC2 knock-out mice (- / -) are adipocyte-specific SPTLC2 deficient mice.

(A) producing a mouse having a floxed SPTLC2 mouse and an adiponectin-Cre transplanted gene; (b) crossing a plastost SPTLC2 mouse with a mouse having an adiponectin-Cre transplantation gene to obtain a second-generation mouse; And (c) selecting an adipocyte-specific SPTLC2 gene-deficient mouse from the second-generation mouse, wherein SPTLC2 exon1 is deleted.

(I) administering a sample to an animal model of lipodystrophy; (ii) measuring the symptoms of lipodystrophy of the animal model after administration of the sample; And (iii) selecting a sample that alleviates the symptoms of lipodystrophy in comparison with a control group to which the sample is not administered. The present invention also provides a method of screening for a therapeutic and / or therapeutic agent for lipodystrophy.

Further, in an embodiment of the present invention, said measurement of step (e) comprises measuring ceramide, sphingomyelin, sphingoid base and diacylglycerol of epididymal WAT; Measurement of plasma ceramide, dihydroceramides, sphingomyelin and sphingoid bases; Measurement of liver cholesterol and liver triglyceride (TG), measurement of expression of TG biosynthesis gene and fatty acid oxidase gene; Measurement of ceramide, sphingomyelin, sphingoid base and diacylglyceride; And measuring the expression of genes that synthesize fats in the skeletal muscle.

The animal model according to the present invention can be used as an animal model of progression of lipodystrophy and pathological mechanism study because it causes lipid disorder such as fatty liver, systemic insulin resistance and hypertonic ptosis due to adipocyte-specific SPTLC2 gene deletion have.

Therefore, the animal model according to the present invention can be very usefully used for screening for selecting a substance for controlling lipodystrophy and verifying its therapeutic effect.

Hereinafter, the present invention will be described in more detail by way of examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

< Example >

One. Materials and Methods

(One) Hyperinsulinemia Normal blood glucose clamp and glucose flux calculation

Eight days before clamping, the catheter was placed in the right jugular vein. Basal / continuous infusion of human insulin (21.4 mU / kg for basal infusion and 3 mU / kg / min for continuous infusion, Eli Lilly) to maintain normal blood glucose (approximately 130 mg / dl) At the same time, 20% dextrose was injected variably and hyperinsulinemic normal blood glucose clamp test was performed for 120 minutes.

(2) Cell culture

Mouse 3T3-L1 cells were obtained from the Korea Research Institute of Bioscience and Biotechnology, KRIBB, Korea. The cells 10% elegant serum (Bovine Calf Serum, BCS), 10 units / ml penicillin, 10 μg / ml streptomycin (P / S) the insert had the animal cell culture in a culture medium of DMEM, 37 ℃ and 5% CO ₂ Lt; / RTI &gt;

(3) Transient transfection and reporter genes Assay

The vector containing PPRE-x3-TK-luc (plasmid 1015; Addgene) construct was transiently transfected into AML-12 cells using Lipofectamine 2000 (Invitrogen). In order to standardize the transfection efficiency, the expression vector pTK-RL for Renilla luciferase was used.

(4) RNA preparation and quantitative RT- PCR

Total RNA was isolated from 3T3-L1 cells or liver tissue, and gene expression was determined by analyzing the complementary DNA synthesized therefrom. The primer sequences used in this experiment are shown in Table 1 below.

gene Primer base sequence β-actin F GAC GTT GAC ATC CGT AAA G (SEQ ID NO: 1) R CAG TAA CAG TCC GCC T (SEQ ID NO: 2) GAPDH F CAA GGT CAT CCA TGA CAA CTT TG (SEQ ID NO: 3) R GGC CAT CCA CAG TCT TCT GG (SEQ ID NO: 4) SPTLC1 F AGT GGT GGG AGA GTC CCT TT (SEQ ID NO: 5) R CAG TGA CCA CAA CCC TGA TG (SEQ ID NO: 6) SPTLC2 F GGA TAC ATC GGA GGC AAG AA (SEQ ID NO: 7) R ACC TGG TGT TCT CAG CCA AC (SEQ ID NO: 8) SPHK1 F TGT GAA CCA CTA TGC TGG GTA (SEQ ID NO: 9) R CAG CCC AGA AGC AGT GTG (SEQ ID NO: 10) SPHK2 F AGA CGG GCT GCT TTA CGA G (SEQ ID NO: 11) R CCT GCT CAA ACC CGC CAT (SEQ ID NO: 12) aP2 F GAA CCT GGA AGC TTG TCT TCG (SEQ ID NO: 13) R ACC AGC TTG TCA CCA TCT CG (SEQ ID NO: 14) C / EBPα F GAA CAG CAA CGA GTA CCG GGTA (SEQ ID NO: 15) R GCC ATG GCC TTG ACC AAG GAG (SEQ ID NO: 16) PPARγ F GAG TGT GAC GAC AAG ATT TG (SEQ ID NO: 17) R GGT GGG CCA GAA TGG CAT CT (SEQ ID NO: 18) PEPCK F CCC CTT GTC TAT GAA GCC CTC A (SEQ ID NO: 19) R GCC CTT GTG TTC TGC AG (SEQ ID NO: 20) SREBP-1c F CGG AAG CTG TCG GGG TAG (SEQ ID NO: 21) R GGC CAG AGA AGC AGA AGA GA (SEQ ID NO: 22) GLUT4 F AGA GTC TAA AGC GCC T (SEQ ID NO: 23) R CCG AGA CCA ACG TGA A (SEQ ID NO: 24) FAS F CAG ATG ATG ACA GGA GAT GGA A (SEQ ID NO: 25) R CAC TCA CAC CCA CCC AGA (SEQ ID NO: 26) DGAT1 F GTG CCA TCG TCT GCA AGA TTC (SEQ ID NO: 27) R GCA TCA CCA CAC ACC AAT TCA G (SEQ ID NO: 28) DGAT2 F CTG TCA CCT GGC TCA ACA GA (SEQ ID NO: 29) R TAT CAG CCA GCA GTC TGT GC (SEQ ID NO: 30) HMG CoR F GGG AAC TAT TGC ACC G (SEQ ID NO: 31) R GTA GCC GCC TAT GCT C (SEQ ID NO: 32) LpL F TCT GTA CGG CAC AGT GG (SEQ ID NO: 33) R CCT CTC GAT GAC GAA GC (SEQ ID NO: 34) CPT1α F CCA TCC TGT CCT GAC AAG GTT TAG (SEQ ID NO: 35) R CCT CAC TTC TGT TAC AGC TAG CAC (SEQ ID NO: 36) CPT1? F GGT CCC ATA AGA AAC AAG ACC TCC (SEQ ID NO: 37) R CAG AAA GTA CCT CAG CCA GGA AAG (SEQ ID NO: 38) ACOX1 F ACG CCA CTT CCT TGC TCT TC (SEQ ID NO: 39) R AGA TTG GTA GAA ATT GCT GCA AA (SEQ ID NO: 40) LCAD F TTT CCT CGG AGC ATG ACA TTT T (SEQ ID NO: 41) R GCC AGC TTT TTC CCA GAC CT (SEQ ID NO: 42) MCAD F AAC ACT TAC TAT GCC TCG ATT GCA (SEQ ID NO: 43) R CCA TAG CCT CCG AAA ATC TGA A (SEQ ID NO: 44) S1P ₁ F ATG GTG TCC ACT AGC ATC CC (SEQ ID NO: 45) R CGA TGT TCA ACT TGC CTG TGT AG (SEQ ID NO: 46) S1P ₂ F ACA GCA AGT TCC ACT CAG CAA (SEQ ID NO: 47) R CTG CAC GGG AGT TAA GGA CAG (SEQ ID NO: 48) S1P ₃ F ACT CTC CGG GAA CAT TAC GAT (SEQ ID NO: 49) R CCA AGA CGA TGA AGC TAC AGG (SEQ ID NO: 50) CD36 F ATT GGT CAA GCC AGC T (SEQ ID NO: 51) R TGT AGG CTC ATC CAC TAC (SEQ ID NO: 52) ACC F CGC CAA CAA TGG TAT TGC AGC (SEQ ID NO: 53) R TCG GAT TGC ACG TTC ATT TCG (SEQ ID NO: 54)

(5) Immune Blot ( Immunoblot ) analysis

Tissues or cells were homogenized in cell lysis buffer. 30 μg of the protein was used in the immunoblotting method as described in the prior art (Lee, SY, Lee, HY, et al., Hepatology, 2015, 62, 135-146) . The blot was developed with an enhanced chemiluminescent substrate (Millipore, Bilecica, MA) and detected using a Fusion Solo chemiluminescent imaging analyzer (Vilber Lourmat, Germany) with a Fusion Solo.

(6) Metabolite  Measure

Blood glucose level, plasma and liver TG (triglyceride), cholesterol, HDL, LDL and unesterified fatty acids. The sphering loop feed levels in plasma and tissue were determined by liquid chromatography / tandem mass spectrometry (LC / MS / MS) as described in the prior art (Lee SY, Hong IK, Kim BR , Shim SM, Sung Lee J, Lee HY, et al., Hepatology, 2015, 62, 135-146).

(7) histology

The liver was separated and frozen in medium containing OCT. Adipose tissue was detached and fixed in 10% buffered formalin for 24 hours. 5 μm sections of either paraffin-fixed or frozen tissue were stained with hematoxylin and eosin (H & E, Sigma-Aldrich) or stained with Oil Red O (ORO). Macrophages were detected with F4 / 80 antibody.

(8) Statistical analysis

Results are expressed as mean ± standard error (SEM). The difference between the groups was determined as a two-tailed unpaired Student t test. P <0.05 was considered statistically significant.

2. result

(One) Sphing ring feed  Neoplastic synthesis is upregulated in adipose tissue during adipocyte differentiation under obesity conditions.

WAT (white adipose tissue) hypertrophy is caused by increased delivery of FA (fatty acid) to WAT and activated TG (triglyceride) synthesis by obesity. Since FA is a substrate for sphingolipid biosynthesis, the inventors of the present invention investigated whether sphingolipid metabolism changes in the WAT of epididymis derived from mice fed high-fat diet (HFD).

As a result of 8 weeks of 60% high-fat diet (HFD) results, SPTLC2, SPHK1, aCer2 (alkaline ceramidase2), aCer3, CerS2 (ceramide synthase2) and DES1 (dihydroceramide desaturase 1) of WAT were upregulated (FIG. 1A). In particular, the elevation of elevated SPTLC2 mRNA and protein indicates the activation of sphingolipid neogenesis. Up-regulation of DES1, CerS2, aCer2 / 3 and SPHK1 suggests that the overall metabolic flux, starting from the SPT catalytic phase, shifts to the synthesis of S1P (sphingosine 1-phosphate) via ceramide in the obese condition 1A, B).

SPTLC2, SPHK1, aCer1 / 2/3, AcCer (acid ceramidase) and nCer (neutral ceramidase) were up-regulated in a time-dependent manner during the differentiation of 3T3-L1 cells (Fig. 1C, E and Fig. 2). On the other hand, the SPTLC2 protein level was decreased and the SPTLC1 protein level was not changed (Fig. 1D). SPHKl, the endpoint of this upregulation in the sphingolip feed biosynthetic branch, was upregulated in the later stages of adipocyte differentiation as reported in the prior art (Hashimoto T, Igarashi J, Kosaka H., J Lipid Res, 2009 , 50, 602-610). These results indicate that sphingolipid neogenesis in adipose tissue is upregulated during transcription during adipocyte differentiation under obesity conditions.

(2) SPTLC2  Inhibition reduces lipogenesis and downregulates lipogenic genes.

Observations that SPTLC2 was upregulated at transcription in obese adipose tissue and differentiated 3T3-L1 cells suggests that sprint cyclic neogenesis may be required for WAT differentiation. To confirm this hypothesis, the inventors of the present invention prepared a lentivirus having a SPTLC2 shRNA (short hairpin RNA) and infected 3T3-L1 cells to suppress SPTLC2 expression. shRNA (short hairpin RNA) mediated down-regulation of SPTLC2 was confirmed by measuring mRNA and protein (Fig. 3A, B). During differentiation, 3T3-L1 cells with suppressed SPTLC2 expression accumulated less fat than control 3T3-L1 cells (Fig. 3C).

Next, the inventors of the present invention measured the mRNA levels of adipogenic factors during fat production. Although there was little change at the SPHK1 level, the adipocyte saturation genes SPHK2, aP2, C / EBPa, PPARy, PEPCK, SREBP-lc and GLUT4 were downregulated (Fig. 3D, E) . These results indicate that sphingolipid neogenesis plays an important role in the differentiation of 3T3-L1 adipocytes by regulating the expression of obesity genes.

(3) Adipocyte-specific SPTLC2  Deficiency Adipose  Cause.

Next, the inventors of the present invention investigated whether adipocyte specific SPTLC2 deficiency (aSPTLC2 KO) changes the development of adipose tissue in mice. The inventors of the present invention produced an aSPTLC2 KO mouse by crossing a floxed SPTLC2 mouse with a mouse having the adiponectin-Cre transplantation gene. When SPTLC2 expression was examined in multiple tissues derived from aSPTLC2 KO mice, SPTLC2 was not detected in epididymal and subcutaneous WAT (FIG. 4A).

In particular, no fat pads were found in male aSPTLC2 KO mice fed a normal diet (NCD), and even when feeding 45% high fat diet (HFD) for 8 weeks, the epididymal and subcutaneous fat pad , Pads of epididymal and subcutaneous fat were scarcely observed in male aSPTLC2 KO mice (Fig. 4B).

The fat cell size of the epididymal WAT of aSPTLC2 KO mice was smaller than that of plucked mice (FIG. 4C).

There was also severe macrophage infiltration in the epididymal WAT of aSPTCL2 KO mice. SPHK2 was up-regulated in WAT for aSPTCL2 KO mice, while most lipo-saturation, including SPHK1, aP2, C / EBPa, PPARy, PEPCK and SREBP-1c, as found in SPTLC2-inhibited 3T3- The gene was not down-regulated or detected (Figure 4D).

Examination of the effect of aSPTLC2 deficiency in the WAT sphingolip feed profile revealed that the C18: 1 sphingomyelin (SM) was reduced while the C16: 0 and C24: 1 ceramides were elevated (Fig. 4E).

In addition, while sphinganine (SA) and sphingosine (SO) were elevated, S1P decreased sharply (Fig. 4F). There was also no change in DAG levels except for a small increase in C18: 1 / C18: 1 DAG (diacylglycerol). The plasma sphingolipid profile was not significantly altered by aSPTLC2 deficiency, and elevated ceramide, dihydroceramides, and SM appeared only in flocked mice fed high-fat diet (HFD) (Fig. 5). These results suggest that defects in sphingolipid neogenesis alter fat sphingolipid composition and prevent the development of adipose tissue.

(4) Fatty acids that are not accumulated in adipose tissue accumulate in the liver, and fatty acids are generated in the mouse.

Since the aSPTLC2 KO mouse has a significantly reduced fat pool and very small adipose tissue, the inventors of the present invention investigated whether the excess fat was redistributed to peripheral tissues such as the liver. High-fat diet (HFD) resulted in fat accumulation in the liver in both the plastose and aSPTLC2 KO mice, whereas in the group fed the normal food diet (NCD), the aSPTLC2 KO mice showed a high fat accumulation (Fig. 6A) .

aSPTLC2 deficiency did not alter liver cholesterol levels and high-fat diet (HFD) groups showed reduced levels of liver cholesterol in both plastost and aSPTLC2 KO mice compared to the normal diet (NCD) group (FIG. 6B). It is noteworthy that liver TG levels were not changed in aSPTLC2 KO mice fed high fat diet (HFD) (FIG. 6B).

To determine whether this phenomenon was due to activated lipid biosynthesis or inhibited FA oxidation, we examined the expression of lipid metabolism genes. As a result, sterol response element binding protein (SREBP) -1c, fatty acid synthase (FAS), diacylglycerol acyltransferase (DGAT) and HMG CoA reductase HMG CoR) was up-regulated in the liver of aSPTLC2 KO mice fed a normal diet (NCD) (Fig. 6C). Expression patterns of aSPTLC2 KO mice fed high - fat diet (HFD) were increased. In particular, the rapid upregulation of FA-transporter CD36 in the liver of aSPTLC2 KO mice suggests increased FA uptake from plasma to liver. In contrast, the FA oxidase gene was not significantly altered in the liver of aSPTLC2 KO mice (Figure 6D).

The effect of aSPTLC2 deficiency on the sphingolipid profile in the liver of the mice was tested in the aSPTLC2 KO mice fed with normal diet (NCD) and high fat diet (HFD), and only C24: 0 and C24: 1 ceramides (Fig. 6E). C18: 0 SM was elevated in the liver of both high-fat diet (HFD) and aSPTLC2 KO mice (Fig. 6E).

The levels of sphinganine (SA) and sphingosine (SO) in the liver of aSPTLC2 KO mice fed high fat diet (HFD) decreased, but there was no change in liver of mice fed a normal diet (NCD) 6F). On the other hand, S1P was elevated only in the liver of flocked mice fed high-fat diet (HFD). DAG levels were elevated in the liver of aSPTLC2 KO mice fed a normal food diet (NCD), whereas high fat diet (HFD) produced increased DAG in the liver of plucked mice (FIG. 6F).

In contrast, the expression of the TG biosynthesis gene in skeletal muscle was not altered by aSPTLC2 deficiency (Fig. 7). These results suggest that defects in sphingolipid neogenesis in adipose tissue and consequent lipodystrophy activate TG biosynthesis in the liver and cause fatty liver.

(5) aSPTLC2  The KO mouse Hyperglycemia  cause.

The aSPTLC2 KO mice did not show any significant change in body weight, whereas the plasma glucose levels of aSPTLC2 KO mice were elevated compared to the flocked mice regardless of diet (Table 2).

NCD HFD SPT Flox (n = 6) aSPTLC2 KO (n = 6) SPT Flox (n = 5) aSPTLC2 KO (n = 6) Body weight (g) 24.1 ± 0.2 25.6 ± 0.5 ^* 26.2 ± 0.6 ^# 26.2 ± 0.5 Plasma glucose (mg / dL) 100.6 ± 2.7 152.7 ± 7.3 ^* 95.8 ± 9.5 145.6 ± 11.8 ^* ALT (U / L) 38.8 ± 10.2 19.3 ± 7.4 33.9 ± 7.7 92.3 ± 26.8 ^* AST (U / L) 156.1 ± 52.1 141.9 ± 32.4 135.3 ± 31.4 206 ± 57.9 T-CHO (mg / dl) 95.8 ± 4.3 117.3 ± 4.4 ^* 170.7 ± 18.9 156.1 ± 28.5 TG (mg / dl) 117.8 ± 11.2 115.7 ± 13.6 86.4 ± 9.5 88.2 ± 18.4 HDL (mg / dl) 64.6 ± 3.2 81.4 ± 2.9 ^* 113.7 ± 12.8 103.6 ± 15.4 LDL (mg / dl) 12.1 ± 0.8 12.3 ± 0.8 23.5 ± 3.6 20.5 ± 5.7 NEFA (mEq / L) 12.8 ± 0.5 9.8 ± 1.0 ^* 10.5 ± 1.3 9.5 ± 0.3 ^* β-OH butyrate (μM) 100.6 ± 19 188.3 ± 32 ^* 102.5 ± 28 137.5 ± 10

Alanine transaminase (ALT) activity was increased in aSPTLC2 KO mice fed high-fat diet (HFD) and there was no change in the activity of aspartate aminotransferase (AST). Plasma cholesterol levels were increased in aSPTLC2 KO mice fed a normal diet (NCD), which is consistent with an upregulated HMG CoR (FIG. 6C).

Surprisingly, plasma nonesterified fatty acid (FA) levels in aSPTLC2 KO mice with lipodystrophy fed normal diet (NCD) or high fat diet (HFD) decreased (Table 2). The ketone body, represented by beta-hydroxybutyrate, increased only in aSPTLC2 KO mice fed normal food diet (Table 2). In summary, the fat that should be accumulated in adipose tissue is presumed to have accumulated in the liver instead of through increased CD36-mediated FA transport and activated TG biosynthesis.

(6) Adipose aSPTLC2  KO mice are insulin-resistant.

Plasma glucose levels were elevated in aSPTLC2 KO mice fed either normal diet (NCD) or high fat diet (HFD), as reported in patients with lipid disorders (Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB., J Endocrinol, 2010, 207, 245-255, Savage DB., Dis Model Mech, 2009, 2, 554-562, Vernochet C, Damilano F, Mouriere, Bezy O, , et al., FASEB journal, 2014, 28, 4408-4419), and whether SPTLC2 KO-mediated fatty liver causes liver insulin resistance. First, the inventors of the present invention measured the sperm composition after feeding a 60 kcal% high-fat diet (HFD) to flockst and aSPTLC2 KO mice for 4 weeks. Flocked mice fed high-fat diet (HFD) gained weight in a time-dependent manner when compared to mice fed a normal diet (NCD) (Fig. 8A).

During this period, food intake associated with diets was not changed in plastock and aSPTLC2 KO mice (Fig. 9). On the other hand, the weight of aSPTLC2 KO mice was slightly higher than that of Flockst mice, but the weight did not change during high fat diet (HFD). In addition, the energy consumption of the mice was measured for 24 hours, but there was no change in oxygen consumption (VO2), carbon dioxide production rate (VCO2), respiratory energy exchange ratio (RER), energy consumption or food intake (FIG. However, an increase was observed only in the activity of aSPTLC2 KO mice fed with normal food diet (NCD).

Next, the inventors of the present invention measured the body composition characterized by lean body mass using ¹ H-NMR. Flocked mice showed a rapidly increased fat content and reduced fat exclusion mass when fed high fat diet (HFD), whereas aSPTLC2 KO mice showed no change in body weight and body composition (FIG. 8B).

Then, in order to examine insulin resistance in aSPTLC2 mice, a hyperinsulinemic normal blood glucose clamp experiment was performed. Fasting blood glucose levels in aSPTLC2 KO mice were elevated compared to fasting glucose levels in flocked mice fed high-fat diet (HFD) (Fig. 11).

In addition, glucose uptake rate was decreased in aSPTLC2 KO mice fed high fat diet (HFD) (Fig. 8C). In aSPTLC2 KO mice, inhibition of hepatic glucose production was decreased and hepatic glucose production was increased (Fig. 8C-D).

On the other hand, there was no change in glucose uptake, glycolysis and glycogen synthesis (FIG. 11B-D). These results suggest that liver-specific insulin resistance occurs in aSPTLC2 KO mice. To further investigate changes in the insulin signaling system, insulin (0.5 mg / kg) was injected for 10 minutes and the degree of phosphorylation of AKT was measured. Insulin-mediated phosphorylation of AKT was reduced in both liver and adipose tissue of aSPTLC2 KO mice (Fig. 8E-F).

Taken together, these results suggest that increased insulin resistance in the aSPTLC2 KO mice is due to liver insulin resistance associated with fatty liver.

(7) aSPTLC2  Deficiency S1P  Reduce the level S1P _One  The receptor is down-regulated.

The inventors of the present invention sought to determine whether reduced fat S1P levels were associated with lipid abnormalities that appeared in aSPTLC2 KO mice (Fig. 4F).

As described in the prior art, 60% of the mice were injected into the plastost and aSPTLC2 KO mice, as described in the previous literature (Lee SY, Hong IK, Kim BR, Shim SM, Sung Lee J, Lee HY, et al., Hepatology, 2015, 62, 135-146) High - fat diet (HFD) was fed for 2 weeks and SPHK2 adenovirus was injected to increase plasma S1P and sperm composition for an additional 2 weeks. Cell size increased in adipocytes of SPHK2 adenovirus-injected plastose and aSPTLC2 KO mice as compared to mice injected with GFP-control adenovirus (Figure 12A).

Fat tissue mass in aSPTLC2 KO mice was not altered by GFP or SPHK2 adenovirus, whereas fat tissue was significantly increased in SPHK2 adenovirus-infected plucked mice (FIG. 12B). These results indicate that extracellular S1P plays a role in adipocyte hypertrophy.

Next, expression of S1P receptor in adipose tissue was measured. As a result, it was found that S1P ₁ was abruptly down-regulated and S1P ₂ and S1P ₃ were up-regulated in aSPTLC2 KO WAT (Fig. 12C).

It was S1P ₁ is significantly down-regulation in the 3T3-L1 cells treated with SPTLC2 shRNA, on the other hand, the S1P ₂ or S1P ₃ expression was not characteristic changes (Figure 12D-F). Thus, these results suggest that the S1P ₁ receptor-mediated S1P signaling pathway plays an important role in the proliferation or differentiation of adipocytes.

(8) S1P PPAR ( peroxisome proliferator -activated receptor) Through γ activation, pre-adipocytes (pre- adipocytes ) And induces fat production.

A previous report that increased plasma S1P increased adipocyte differentiation (Hashimoto T, Igarashi J, Kosaka H., J Lipid Res, 2009, 50, 602-610) suggests that S1P increases adipocyte proliferation or lipogenesis . To investigate this, 3T3-L1 cells were treated with S1P and their proliferation was examined. As S1P levels were increased, pre-adipocytes 3T3-L1 cells increased in a dose-dependent manner (Fig. 13A).

The reduced clearance following S1P treatment suggests that S1P is a proliferative factor of adipocytes (Fig. 13B). In addition, S1P-dependent increase in cell viability indicates that S1P promotes cell proliferation (Fig. 13C).

A recent report suggests that S1P is a ligand for the peroxisome proliferator-activated receptor (PPAR) gamma, independently of the S1P receptor in endothelial cells (Parham KA, The inventors of the present invention have found that after the S1P treatment for 6 hours, the known PPARgamma agonist (Zebol JR, Tooley KL, Sun WY, Moldenhauer LM, Cockshell MP, et al., FASEB journal, 2015, 29, 3638-3653) The activity of the peroxisome proliferator-activated receptor response element (PPRE) reporter was measured using rosiglitazone as a positive control. As a result, S1P treatment increased PPRE-luciferase reporter activity to a level similar to the activity level generated by treatment with rosiglitazone (Fig. 13D). These results suggest that adipocyte proliferation and lipogenesis are regulated by S1P.

3. discussion

Sphingolipids are important regulators in cell proliferation and differentiation, and metabolic dysregulation of sphingolipids results in major metabolic diseases and cardiovascular diseases, including hypertension, hyperglycemia and dyslipidemia. Inhibition of sphingolipid neogenesis has been reported to improve obesity-associated insulin resistance and WAT differentiation.

In this experiment, we attempted to explain the link between sphingolipid biosynthesis and adipocyte proliferation / differentiation, and the following were identified: 1) during adipocyte differentiation, the sphingolipid biosynthetic flow shifts towards S1P biosynthesis; 2) inhibition of sphingolipid neogenesis inhibits adipocyte differentiation; 3) Adipocyte-specific SPTLC2 deficiency causes lipodystrophy, fatty liver and systemic insulin resistance; 4) S1P and S1P ₁ Receptors are associated with proliferation and differentiation of adipocytes. These experiments explain the interferences to FA / TG storage between liver and adipose tissue and indicate that sphingolipid metabolites play an important role in lipogenesis.

The inventors of the present invention have found that expression of SPTLC2 and SPHK1 is increased in adipose tissue of mice fed high-fat diet (HFD). Nutritional excess, expressed as high fat diet (HFD), resulted in increased fat storage in adipose tissue and induction of SPHK1, a lipogenesis factor. During the differentiation of 3T3-L1 cells in mice fed high-fat diet (HFD), the upregulation of the catalytic units SPTLC2, DES1, and some ceramides of the SPT enzymes, suggests that the total sphingolipid biosynthetic flow is directed towards producing S1P It means to move. Interestingly, the expression of SPTLC2 mRNA and protein did not coincide during fat production. This is presumably due to increased proteolysis and a compensatory mechanism to supplement the sphingolip pool in adipocytes, but the main reason for this to date is unclear.

The inventors of the present invention anticipated that genetic suppression of SPTLC2 by shRNA would increase fat storage in 3T3-L1 cells due to increased FA solubility for TG synthesis. Surprisingly, however, the expression of fat accumulation and obesity genes was significantly reduced. It has been reported in the prior art literature that suppressing DES1 and inhibiting sphingolipid neogenesis leads to disturbed fat accumulation and inhibition of obesity genes (Barbarroja N, Rodriguez-Cuenca S, Nygren H, Camargo A, Pirraco A, Relat J, et al., Diabetes, 2015, 64, 1180-1192). These results suggest that the regulation of sphingolipid composition plays a role as a signaling molecule rather than a structural biosynthetic role.

Consistent with the results of 3T3-L1, aSPTLC2 KO mice exhibited severe lipodystrophic phenotypes. High fat diet (HFD) resulted in small increases in adipose tissue in aSPTLC2 KO mice, whereas fat tissue was rarely found in aSPTLC2 KO mice fed a normal food diet (NCD). In adipose tissue of aSPTLC2 KO mice, the expression of SPHK1 and other obese genes was markedly decreased and the adipose tissue cell size was reduced (FIG. 4). In particular, the aSPTLC2 KO adipose tissue showed increased levels of ceramide and sphingoid bases, including sphingosine (SO) and sphinganine (SA), even in the absence of the sphingolipid biosynthetic pathway. This may be due to blood circulation or supply from other intact cells, and is also insufficient to restore disturbed adipocyte proliferation and differentiation, but may be due to compensatory upregulation of SPHK2. On the other hand, the total amount of WAT in aSPTLC2 KO mice is too small to determine if the sphingolipid biosynthetic system is intact and can contribute to the systemic fat pool.

Fatty dystrophy, which is a deficiency of adipose tissue, can be localized, partial, or generalized. Generally, in patients with lipodystrophy, fat is redistributed to the peripheral organs. These ectopic fats are a major cause of metabolic dysfunctions such as insulin resistance, fatty liver and hypertriglyceridemia. Consistent with these reports, aSPTLC2 KO mice show lipid redistribution in the liver. Even when fed a normal food diet (NCD), fatty liver was developed in the liver of aSPTLC2 KO mice through upregulated CD36. Surprisingly, in this case, plasma TG and non-esterified fatty acid (NEFA) levels did not change. This is probably because of increased FA absorption in the liver by up-regulated CD36, which leads to maintenance of homeostasis in the blood circulation. In the liver, FAs transported are used for TG synthesis, and the TG biosynthetic system is activated throughout the enterprise. aSPTLC2 KO mice also showed hyperglycemia, another characteristic of lipodystrophy. This is mainly due to increased hepatic glucose production and inhibition of insulin action on liver inhibition. This is not due to ceramide that has not been elevated in the liver. On the other hand, elevated liver DAG (diacylglycerol) probably contributed to the disturbed insulin signaling system.

The phenotype of lipodystrophy presented by aSPTLC2 KO mice is similar to that of congenital generalized lipodystrophy (CGL). The most common cause of congenital generalized dyslipidemia is the synthesis of phosphatidic acid which is involved in the synthesis of 1-acylglycerol-3-phosphate O-acyltransferase 2 , AGPAT2). In particular, heterozygous mutations in PPARγ have been found in patients with familial partial lipodystrophy, which will likely disturb adipocyte differentiation. Recently, Parhan et al. Reported that S1P is a ligand for PPARγ in human endothelial cells (Parham KA, Zebol JR, Tooley KL, Sun WY, Moldenhauer LM, Cockshell MP, et al., FASEB journal, 2015; 29: 3638-3653).

The inventors of the present invention have confirmed S1P-mediated PPARgamma activation and thus S1P depletion resulting from aSPTLC2 deficiency will partly interfere with PPARgamma activation and lead to inhibition of adipocyte differentiation. Furthermore, S1P receptors are independently involved in the proliferation and differentiation of adipocytes. When plasma S1P levels were elevated by SPHK2 adenoviral overexpression in the liver, both plastock and aSPTLC2 KO mice showed adipocyte hypertrophy (Fig. 12A). On the other hand, the increased amount of adipose tissue was found only in aplock mice, but not in aSPTLC2 KO mice. The exact reason for this is uncertain at this time. Maintenance of basal S1P receptor expression may be essential and S1P supplementation from blood circulation may be inadequate for restoring the dyslipidemic phenotype in aSPTLC2 KO mice. SPTLC2- in fat cells inhibit the 3T3-L1 during the match, differentiation, these were only discovered that they have only reduced S1P ₁ receptor gene expression. It proposes that recently, S1P _1/3 report that the pharmacological inhibition of the receptor inhibition of fat cell proliferation is S1P ₁ receptor is involved in lipogenesis. This result confirms that S1P activates the proliferation of 3T3-L1 adipocytes in a dose-dependent manner.

Collectively, lipid disorders and fatty liver observed in aSPTLC2 KO mice are a composite result of inhibiting the two actions of PPARγ-mediated lipogenesis and S1P-mediated proliferation. Additional studies are needed to explain the apparent role of S1P receptors in adipocyte formation in the future.

The inventors of the present invention have previously reported that adenoviral overexpression of SPHK2 activates FA oxidation and decreases lipid in the liver of mice fed high-fat diet (HFD) (Lee SY, Hong IK, Kim BR, Shim SM, Sung Lee J, Lee HY, et al., Hepatology, 2015, 62, 135-146). The elevation of S1P activates FA oxidation in the liver. On the other hand, S1P is increased by upregulation of SPHK1 and SPHK2 during 3T3-L1 cell differentiation and contributes to fat production. The in vivo test results of the present invention confirmed that S1P increased as a result of liver overexpression of SPHK2 activates adipocyte hypertrophy and proliferation. The different roles of these S1Ps contribute to the balance of FA / TG distribution and utilization through mutual interference between liver and adipose tissue. In addition, S1P / S1P ₁ Activation of the receptor signaling system has been reported to reduce food consumption and increase energy expenditure in the hypothalamic POMC (pro-opiomelanocortin). Although the functional groups may vary in small liver, adipose tissue and hypothalamus, this report suggests that the S1P signaling system plays an important role in systemic metabolic regulation.

Collectively, the experimental results of the present invention suggest that sphingolipid neogenesis plays an important role in the proliferation and differentiation of adipocytes. Adipocyte-specific blockade of sphingolipid neogenesis inhibits lipogenesis and causes lipid disorders and fatty liver. Among the sphingolipid metabolites, fat and cyclic S1P have been shown to regulate proliferation and differentiation of adipocytes through receptor mediated and PPARy mediated action. In conclusion, S1P suggests that it is a signaling molecule that mediates energy homeostasis and mutual interference between the liver and adipose tissue.

Claims (6)

Wherein the adipocyte-specific SPTLC2 gene is a knock-out mouse.
The animal model of lipodystrophy according to claim 1, wherein the mouse is a homozygote.
The animal model of lipodystrophy according to claim 1, wherein the lipodystrophy is any one selected from the group consisting of fatty liver, systemic insulin resistance and hypertonicity.
(a) preparing a mouse with a floxed SPTLC2 mouse and an adiponectin-Cre transplant gene;
(b) obtaining a second generation mouse by crossing a mouse with a plastose SPTLC2 mouse and an adiponectin-Cre transplantation gene; And
(c) selecting an adipocyte-specific SPTLC2 gene-deficient mouse from the second-generation mouse obtained in step (b);
Lt; RTI ID = 0.0 &gt; exon1 &lt; / RTI &gt; removed.
(i) administering a sample to an animal model of lipodystrophy according to any one of claims 1 to 3;
(ii) measuring the symptoms of lipodystrophy of the animal model after administration of the sample; And
(iii) selecting a sample that alleviates symptoms of lipodystrophy compared to a control group to which the sample is not administered;
The method of screening for a preventive and therapeutic agent for lipodystrophy.
6. The method according to claim 5, wherein the symptom of lipodystrophy in step (ii) is a content of ceramide, sphingomyelin, sphingoid base and diacylglycerol of epididymal WAT; Plasma ceramide, dihydroceramide, sphingomyelin and sphingoid base content; Expression of hepatic cholesterol or liver triglyceride (TG) content, TG biosynthesis gene or fatty acid oxidase gene; The content of ceramide, sphingomyelin, sphingoid base and diacylglyceride; And expression of a lipogenic gene of a skeletal muscle.

Images